Codagenix
PrivateLast Round
Grant
Oct 24, 2023
Total Funding Raised
$65.18M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Codagenix operates in Healthcare & Life Sciences and is based in Farmingdale, New York. Its latest recorded funding round was a Grant round in October 2023.
Codagenix is a biotechnology company that develops live-attenuated viral vaccines and therapeutics using a synthetic biology platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2G
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Codagenix Comparables
Compare Codagenix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CyanVac LLC | 91% | |
| Blue Lake Biotechnology, Inc. | 88% | |
| Vivaldi Biosciences, Inc. | 83% |
For institutional investors. Book with your work email.
Codagenix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 24, 2023 | ||||
| Series B Extension | Feb 15, 2023 | ||||
| Grant | Aug 17, 2022 | ||||
| Grant | Jul 22, 2020 | ||||
| Series B | Jan 14, 2020 | ||||
VC Round | Oct 12, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Codagenix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| U.S. Department of Health and Human Services | Grant |
| United States Department of Defense | Grant |
| US Army Medical Research and Development Command | Grant |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Topspin Fund | Series B, Series A |
| Biomedical Advanced Research and Development Authority | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 447% MoM, from 448 to 2.5K.
- Oct 24, 2023
Received $6M from U.S. Department of Health and Human Services.
For institutional investors. Book with your work email.
Codagenix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Codagenix's valuation, stock price, and market status.
Is Codagenix a public or private company?
Codagenix is a private company.
What is the current stock price of Codagenix?
Codagenix is a private company, so its shares have no public market price. Caplight tracks Codagenix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Codagenix worth (valuation)?
Valuation information for Codagenix is not publicly available.
Can I buy Codagenix stock?
Codagenix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Codagenix's last funding round?
Codagenix's most recent funding round was Grant on October 24, 2023.
Who are the main investors in Codagenix?
Key investors in Codagenix include Topspin Fund, Adjuvant Capital, Euclidean Capital.
Will Codagenix IPO soon?
No public IPO plans have been announced for Codagenix.
How can I track Codagenix secondary market activity?
Caplight tracks bids, offers, and trades in Codagenix's shares on secondary markets.